# A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone

Source: https://onco.cc/trials/nct06952478/  
OnCo record `nct06952478` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daratumumab in multiple myeloma, run by Celltrion, now recruiting.

## Summary

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma is a phase 3 interventional study registered as NCT06952478 by Celltrion, with 486 participants planned, started 2025-08-12 and due to reach its primary completion in 2027-11-15. Interventions recorded: CT-P44(Daratumumab), Darzalex Faspro(Daratumumab). Conditions listed: Refractory or Relapsed Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06952478
- Phase: 3
- Setting: A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
- Sponsor: Celltrion
- Enrolled: 486

## Sources

- ClinicalTrials.gov NCT06952478: https://clinicaltrials.gov/study/NCT06952478

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Daratumumab](https://onco.cc/drugs/daratumumab/)
- companies: [Celltrion](https://onco.cc/companies/celltrion/)

---
JSON: https://onco.cc/api/v1/entities/nct06952478.json